# EVOKE-SCLC-04 (NCT06801834)

> Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06801834
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Gilead Sciences
- Conditions: Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Interventions: Sacituzumab Govitecan (SG); Topotecan; Amrubicin (Japan only); Lurbinectedin (regions/countries where approved and available)
- Enrollment: 695
- Primary outcome: Overall Survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=evoke-sclc-04-nct06801834